// App-Quantinova.ai

POS0435 (2022) : IMPACT OF COMBINATION THERAPY WITH csDMARDs ON THE EFFECTIVENESS OF BIOLOGIC OR TARGETED SYNTHETIC DMARDs IN A REAL-LIFE SETTING: RESULTS FROM THE SWISS RHEUMATOID ARTHRITIS REGISTER (SCQM-RA)

Researchers

Presenter

  • B. Gilbert

Principal Investigators

  • D. Mongin

  • E. Nham

  • D. Courvoisier

  • K. Lauper

  • C. Laedermann

  • R. Mller

  • A. Finckh

Medical Centers

  • Geneva University Hospitals, Division of Cardiology, Geneva, Switzerland

  • Centre for Musculoskeletal Research, University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom

  • Eli Lilly, (Suisse) SA, Vernier, Switzerland

  • Kantonsspital, Division of Rheumatology, Aarau, Switzerland

Locations

  • Switzerland

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Body mass index

Drug/Treatment

  • Baricitinib

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • Eli Lilly and Company

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved